Skip to product information
Pure N-Acetyl Cysteine (NAC) Zero Fillers- 600 mg
$24.95
/ 120 Capsules | 120 Servings
Pure N-acetyl cysteine. Zero fillers. No seed oils. Physician-formulated to replenish glutathione — your body's master antioxidant.* 99%+ purity verified. Third-party tested in a GMP-certified U.S. facility.
Science-Backed Benefits:
Replenishes glutathione levels to reduce oxidative stress*
Supports immune and respiratory health*
Promotes liver function and detoxification pathways*
Helps support mitochondrial health and exercise recovery*
Physician Formulated
GMP Certified
Made in the USA
Bring Life to Your Years™
Physician-formulated and third-party tested for purity and potency
Manufactured in a GMP-certified U.S. facility
Free from seed oils, gluten, soy, dairy, GMOs, and fillers
Shelf-stable, light-protective packaging
Backed by the MyGevity™ standard of clean, science-based longevity
Physician Formulated
GMP-Certified Facility
Vegan
No Seed Oils
GMO-Free
Gluten Free
Third Party Lab Tested
Made in the USA
Other Ingredients
Free From:
Milk, eggs, fish, shellfish, tree nuts, peanuts, wheat, soy, gluten, GMOs, artificial colors, preservatives, and seed oils.
Resources and References
Study 1
The promise of N‐acetylcysteine in the treatment of obsessive‐compulsive disorder
Journal:
CNS Neurosci Ther. 2024 Feb 22;30(2):e14653. | PMID: 38385640
Summary:
This letter to the Journal is intended to raise awareness within the scientific community about the potential use of N‐acetylcysteine (NAC) as an alternative treatment for obsessive‐compulsive disorder (OCD), primarily targeting glutamatergic system dysfunctions and modulating inflammatory cytokines.
Study 2
The antioxidant N-acetylcysteine promotes immune response and inhibits epithelial-mesenchymal transition to alleviate pulmonary fibrosis in chronic obstructive pulmonary disease by suppressing the VWF/p38 MAPK axis
Journal:
Molecular Medicine, Volume 27, article number 97, (2021)
Summary:
Collectively, NAC could ameliorate COPD-induced pulmonary fibrosis by promoting immune response and inhibiting EMT process via the VWF/p38 MAPK axis, therefore providing us with a potential therapeutic target for treating COPD.
Study 3
N-Acetylcysteine Improves Liver Function in Patients with Non-Alcoholic Fatty Liver Disease
Journal:
Hepat Mon. 2010 Mar 1;10(1):12–16. | PMID: 22308119
Summary:
The current study described the effectiveness of a three-month consumption of NAC in patients with NAFLD, which resulted in a decrease in the level of ALT and in the size of the spleen, compared to those patients taking vitamin C. To our knowledge, few studies have been carried out to examine the implication of NAC on liver function in patients with NAFLD, and in particular on liver hemodynamics.
Study 4
The role for N-acetylcysteine in the management of COPD
Journal:
Int J Chron Obstruct Pulmon Dis. 2006 Jun;1(2):99–106 | PMID: 18046886
Summary:
Oxidative stress is considered to be an important part of the inflammatory response to both environmental and internal signals. Transcription factors like NF-kb and AP-1 are activated by oxidative stress and in turn amplify the inflammatory response to noxious stimuli. In this way, both oxidative stress and inflammation are involved in the complex pathophysiology of COPD, both in terms of pathogenesis and progression of the disease.